Meriofert

Follicle-Stimulating Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It treats infertility‑related conditions in women, such as anovulation, and supports ovarian stimulation for assisted reproductive technologies.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert, a gonadotropin used in reproductive endocrinology, is indicated for: - Induction of ovulation in women with anovulation or oligo‑ovulation: stimulates follicular development to achieve ovulation. - Controlled ovarian stimulation for assisted reproductive technologies (e.g., IVF): supports multiple follicle growth for egg retrieval. - Treatment of hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore normal ovarian function.

Adverse reactions to Meriofert may vary in frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the injection site. - Headache: transient headache of mild to moderate intensity. - Nausea: occasional nausea, often self‑limiting. - Ovarian hyperstimulation syndrome (mild): abdominal bloating and mild discomfort.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): significant abdominal distension, ascites, thromboembolic events. - Thromboembolic complications: deep vein thrombosis or pulmonary embolism. - Allergic reaction: anaphylaxis, urticaria, or angioedema.

When prescribing Meriofert, clinicians should consider several safety and handling precautions. - Patient assessment: evaluate ovarian reserve and baseline hormone levels before initiation. - Monitoring: perform regular ultrasound and estradiol monitoring to detect ovarian hyperstimulation. - Contraindications: avoid use in pregnancy, active ovarian cysts, or uncontrolled thyroid disease. - Drug interactions: review concomitant use of estrogen‑containing products that may alter response. - Thrombotic risk: assess personal or family history of thromboembolic disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other medicines that influence hormone levels or coagulation.

Major Interactions (Avoid): - Estrogen therapy: may increase risk of ovarian hyperstimulation. - Anticoagulants: heightened risk of bleeding when severe OHSS occurs. - GnRH agonists/antagonists: concurrent use requires dose adjustment to avoid excessive stimulation.

Moderate Interactions (Monitor Closely): - Thyroid hormones: altered metabolism may affect response to gonadotropins. - Corticosteroids: may mask early signs of OHSS. - Dopamine agonists: can interfere with prolactin regulation and ovarian response.